Capsovision, Inc (CV) Stock Price & Analysis

Capsovision, Inc (CV) rose 6.18% to USD 6.36 as of September 9, 2026 at 12:40 UTC, according to Nexqual real-time market data.

CV last closed at USD 6.36; the session ranged USD 5.99–6.99 on volume of 391,103 shares. Market capitalization is —, with a 52-week range of USD 3.5–15.37 (NCM). Source: Nexqual, September 9, 2026 at 12:40 UTC.

Key Statistics (as of September 9, 2026 at 12:40 UTC)

Technical Analysis (CV)

Nexqual's technical model rates CV "NEUTRAL" based on 2 bullish and 3 bearish signals across 127 daily candles, as of September 9, 2026 at 12:40 UTC.

From Capsovision, Inc's Latest SEC 10-K Filing (filed 2026-03-26)

Key Strengths & Strategy (as disclosed to the SEC)

• Our CapsoCam Colon (subject to FDA clearance) incorporates our proprietary 3D-sensing technology to more accurately measure polyp sizes.
• For the years ended December 31, 2025 and 2024, we generated approximately $13.6 million and $11.8 million, respectively, in revenue from sales of CapsoCam Plus, an increase of approximately 15% over the prior year.
• Our CapsoCam Colon also incorporates our proprietary 3D-sensing technology to more accurately measure the size of polyps in the GI tract, enabling physicians to more confidently decide that patients with small (e.g., less than 6mm) polyps may forgo a follow-on colonoscopy, increasing the utility of the procedure for healthcare providers and patients alike.
• Building upon the commercial success and the existing design of our CapsoCam Plus capsule, we developed our next pipeline capsule endoscope, CapsoCam Colon.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 9, 2026 at 12:40 UTC. This page is informational and not investment advice.